The effect of hypoglycemic therapy on clinical outcomes in patients with viral pneumonia and type 2 diabetes mellitus

• Olga P. Bubnova
• Tatyana Yu. Demidova
• Kristina G. Lobanova

Abstract

The presence of viral pneumonia (VP) in patients significantly aggravates the course of type 2 diabetes mellitus (TDM2). The infectious process contributes to an increase in blood glucose levels and the development of decompensation of carbohydrate metabolism. On the other hand, hyperglycemia mediates the occurrence of an immunodeficiency state, which leads to a longer persistence of viral agents in the body, and therefore to an increased risk of infectious complications. All patients with VP and TDM2 should receive adequate hypoglycemic therapy aimed at stabilizing glycemic parameters and preventing the development of adverse clinical outcomes in patients with infectious diseases. Therapy with oral hypoglycemic drugs (PSPs) reduces the risk of adverse clinical outcomes in patients with VP and DM2. Insulin therapy (IT) is associated with a higher percentage of mortality compared to PSSP therapy, and IT is justified in patients with VP.

Keywords:viral pneumonia, type 2 diabetes mellitus, hypoglycemic therapy, oral hypoglycemic drugs, insulin therapy

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)